MedPath

A randomised, double-blind, parallel-group comparison of the efficacy and the safety of venlafaxine versus nortriptyline in the treatment of depressed elderly inpatients.

Completed
Registration Number
NL-OMON27258
Brief Summary

1. Int J Geriatr Psychiatry. 2007 Dec;22(12):1247-54. <br>

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
81
Inclusion Criteria

1. Male or female inpatient;

2. Aged 60 years or older;

Exclusion Criteria

1. Known hypersensivity to venlafaxine or nortriptyline;

2. Previous unsuccessful treatment with venlafaxine for at least 4 weeks with a minimum dose of 75 mg/day or previous unsuccessful treatment with nortriptyline for at least 4 weeks with a serum level within the therapeutic range;

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Remission on the MADRS (final score of 10 or less).
Secondary Outcome Measures
NameTimeMethod
Remission on HAM-D and GDS, response on MADRS, HAM-D and GDS, number of side effects, Global Tolerability Score, MMSE, Barthel ADL score, SF-20.
© Copyright 2025. All Rights Reserved by MedPath